Metastatic triple-negative Breast Cancer (mTNBC) - Second-line Therapy mTNBC: Sacituzumab Govitecan with high Effectiveness even in HER2-low

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷 / 7-8期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：343 / 343
页数：1
相关论文
共 50 条
  • [21] Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis
    Carey, Lisa A.
    Loirat, Delphine
    Punie, Kevin
    Bardia, Aditya
    Dieras, Veronique
    Dalenc, Florence
    Diamond, Jennifer R.
    Fontaine, Christel
    Wang, Grace
    Rugo, Hope S.
    Hurvitz, Sara A.
    Kalinsky, Kevin
    O'Shaughnessy, Joyce
    Loibl, Sibylle
    Gianni, Luca
    Piccart, Martine
    Zhu, Yanni
    Delaney, Rosemary
    Phan, See
    Cortes, Javier
    NPJ BREAST CANCER, 2022, 8 (01)
  • [22] Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
    Hegewisch-Becker, S.
    Oliveira, M.
    Traina, T.
    Tolaney, S. M.
    Loirat, D.
    Punie, K.
    Hurvitz, S. A.
    Lynce, F.
    Hamilton, E.
    Nanda, R.
    Hart, L.
    Richards, P.
    Malik, Z.
    Rugo, H. S.
    Dieras, V
    Bardia, A.
    Hong, Q.
    Phan, S.
    Itri, L. M.
    Loibl, S.
    Kalinsky, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 242 - 242
  • [23] Efficacy and safety of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer (mTNBC) by baseline HER2 expression level: Subgroup analysis from a phase IIb trial
    Xu, B.
    Ma, F.
    Wang, S.
    Tong, Z.
    Li, W.
    Wu, X.
    Wang, X.
    Sun, T.
    Pan, Y.
    Yao, H.
    Wang, X.
    Luo, T.
    Yang, J.
    Zeng, X.
    Zhao, W.
    Cong, X. J.
    Wang, N.
    Xu, C.
    Chen, J. J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1438 - S1438
  • [24] Sacituzumab Govitecan for treating Patients with metastatic triple-negative Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (12) : 1271 - 1271
  • [25] Assessment of sacituzumab govitecan (SG) in patients (pts) with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)
    Hegewisch-Becker, S.
    Loirat, D. L.
    Punie, K.
    Bardia, A.
    Dieras, V
    Dalenc, F.
    Diamond, J. R.
    Fontaine, C.
    Wang, G.
    Rugo, H. S.
    Hurvitz, S. A.
    Kalinsky, K.
    O'Shaughnessy, J.
    Carey, L. A.
    Loibl, S.
    Gianni, L.
    Piccart, M.
    Hong, Q.
    Phan, S.
    Itri, L. M.
    Cortes, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 133 - 133
  • [26] A phase III, randomized trial of sacituzumab govitecan (IMMU-132) vs treatment of physician choice (TPC) for metastatic triple-negative breast cancer (mTNBC)
    Bardia, Aditya
    Rugo, Hope S.
    Horne, Heather
    Wegener, William A.
    Goldenberg, David M.
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2018, 78 (04)
  • [27] Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study
    Carrion-Madronal, Isabel Maria
    Diaz-Acedo, Rocio
    Lora-Escobar, Santiago Jose
    Naranjo-Llamas, Eloisa
    Jaramillo-Ruiz, Didiana
    Artacho-Criado, Silvia
    Prado-Mel, Elena
    FUTURE ONCOLOGY, 2024, 20 (33) : 2565 - 2572
  • [28] Real-world outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) in 2L+in the United States (US)
    Kalinsky, Kevin
    Spring, Laura
    Yam, Clinton
    Taylor, Aliki
    Sjekloca, Nikoleta
    Kaushiva, Alpana
    Lai, Catherine
    Ntalla, Ioanna
    Nanda, Rita
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States
    Kalinsky, Kevin
    Spring, Laura
    Yam, Clinton
    Bhave, Manali Ajay
    Ntalla, Ioanna
    Lai, Catherine
    Sjekloca, Nikoleta
    Stwalley, Brian
    Stokes, Michael
    Taylor, Aliki
    Nanda, Rita
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 208 (01) : 203 - 214
  • [30] Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer
    Weiss, Jennifer
    Glode, Ashley
    Messersmith, Wells A.
    Diamond, Jennifer
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (08) : 673 - 679
12345